EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of Combination Androgen‐Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for Poly‐Metastatic Prostate Cancer

Makoto Kawase iD, Kota Kawase iD, Yuki Tobisawa iD, Koji Iinuma iD, Keita Nakane iD, Takuya Koie iD

Cancer Reports · 2025

DOI: 10.1002/cnr2.70355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Makoto Kawase und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan. Hauptthemen laut MEDLINE: Denosumab, Bone Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Androgen Receptor Antagonists. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma Inc., Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Treatment of Metastatic Castration‐Sensitive Prostate Cancer ( mCSPC ) has dramatically changed over the past decade. To improve oncological outcomes, pharmacological treatments have evolved to include two‐or three‐drug combinations, and the efficacy of local radiation therapy ( LRT ) at the prostate combined with denosumab chemotherapy has been discussed.

Aims

This study aimed to provide an interim evaluation of the combination of androgen receptor signaling inhibitors denosumab, LRT , and metastasis‐directed therapy ( MDT ) for prostate cancer with multiple bone metastases (poly‐ PCa ).

Methods

We are currently conducting a single‐arm prospective study to evaluate the combination of enzalutamide, LRT , denosumab, and MDT in terms of improving oncological outcomes in patients with poly‐ PCa . The primary endpoints were prostate‐specific antigen ( PSA )‐based progression‐free survival ( PFS ) and radiographic PFS ( rPFS ).

Results

Twenty patients have been enrolled in the study to date. The median follow‐up period thus far is 18.0 months (interquartile range, 14.0–25.8 months). The 1‐year PFS rate is 84.4% at present, and the rPFS rate is 100%. Seventeen patients (85.0%) achieved a PSA reduction of ≥ 90% versus their baseline values at enrollment, and 10 (50.0%) maintained PSA levels of < 0.2 ng/ mL .

Conclusion

This treatment strategy is expected to improve the oncological outcomes of patients with poly‐ PCa . A more comprehensive report of this study with more patients and a longer observation period is forthcoming.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabBone NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAndrogen Receptor AntagonistsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsChemoradiotherapyHumansMaleProspective StudiesAgedNitrilesPhenylthiohydantoinBenzamidesProstate-Specific AntigenProgression-Free SurvivalMiddle AgedFollow-Up StudiesReceptors, Androgen

Stichwörter der Autor:innen

androgen receptor signaling inhibitordenosumablocal radiation therapymetastasis‐directed therapymetastatic castration‐sensitive prostate cancer

Substanzen

DenosumabNitrilesenzalutamidePhenylthiohydantoinBenzamidesProstate-Specific AntigenAndrogen Receptor AntagonistsAR protein, humanReceptors, Androgen

Autor:innen und Institutionen

  • Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

ORCID-Profile: Makoto Kawase, Kota Kawase, Yuki Tobisawa, Koji Iinuma, Keita Nakane, Takuya Koie

Förderung

  • Astellas Pharma Inc.
  • Astellas Pharma

Zitieren

APA

Kawase, M., Kawase, K., Tobisawa, Y., Iinuma, K., Nakane, K., & Koie, T. (2025). Efficacy and Safety of Combination Androgen‐Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for Poly‐Metastatic Prostate Cancer. Cancer Reports. https://doi.org/10.1002/cnr2.70355

Vancouver

Kawase M, Kawase K, Tobisawa Y, Iinuma K, Nakane K, Koie T. Efficacy and Safety of Combination Androgen‐Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for Poly‐Metastatic Prostate Cancer. Cancer Reports. 2025. doi:10.1002/cnr2.70355

BibTeX
@article{Kawase2025,
  author = {Kawase, Makoto and Kawase, Kota and Tobisawa, Yuki and Iinuma, Koji and Nakane, Keita and Koie, Takuya},
  title = {Efficacy and Safety of Combination Androgen‐Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for Poly‐Metastatic Prostate Cancer},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70355}
}
Kostenlos starten →